This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesDisease AwarenessDisease AwarenessAspergillosisOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseINSPIRE To: Change the Course Season 2The global threat of carbapenemase-producing enterobacterales (CPE)CPE Epidemiology CPE Factsheet London AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Online Learning
INSPIRE To: Change the Course

ICU Collaboration with Radiology in IFI diagnosis to achieve optimal patient-centricity and early outcomes

Dr Hasti Robbie | Consultant Cardiothoracic Radiologist | King’s College Hospital

In this 2-part series, Dr Hasti Robbie provides:

  • The subtypes of IPA and their characteristic pathophysiological features
  • Which patients are most at risk of developing IPA
  • The importance of radiology in diagnosing IPA, and the typical CT signs of IPA

At the end of the course, you will be able to download a certificate of completion.

 

Pulmonary aspergillosis overview and who is 
at risk?

Dr Hasti Robbie provides an overview of IPA and typical signs of the two main subtypes, as well as the patients most at risk of developing IPA.

Learning objectives & questions to consider
Learning objectives:
  • Understand the subtypes of IPA and their characteristic pathophysiological features
  • Recognise the patient risk factors associated with developing IPA
Questions to consider:
  • What are the two main types of IPA, and what distinguishes them from each other?
  • What are the three types of Aspergillus tracheobronchitis, and which type tends to be most severe?
  • Who are the individuals most susceptible to developing IPA?

 

CT signs of Invasive Pulmonary Aspergillosis

Dr Hasti Robbie describes how IPA may appear in CT scans, providing real-world practical examples of the signs to look out for.

Learning objectives & questions to consider​​​​​​Learning objectives:
  • Understand the signs of IPA and how these appear in CT scans
  • Recognise the role of radiology in the diagnosis of IPA
Questions to consider:
  • What are the common CT findings associated with IPA?
  • How is consolidation defined in the context of CT scans, and how does it differ from nodules and masses?
  • What is a halo sign and what does it indicate in IPA?
  • What is an air crescent sign, and when is it a sign of IPA vs other conditions 
like Aspergilloma?
  • What is vessel interruption, and why might its use be limited in IPA?
Certificate Download

Download a certificate to demonstrate your completion of the Hasti Robbie video Series: Collaboration with Radiology in IFI diagnosis to achieve optimal patient-centricity and early outcomes

DownloadLoading
Learn more - Claire Berry 

Radiological & Laboratory Diagnositc approaches for Invasive Fungal Infections - a case study

Go to moduleLoading
CRESEMBA® 
(isavuconazole)

CRESEMBA® (isavuconazole) is indicated in adults for the treatment of Invasive Aspergillosis and also for the treatment of Mucormycosis in patients for whom amphotericin B is inappropriate.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

Learn more
Loading

CT, computed tomography; IFI, invasive fungal infection; IPA, invasive pulmonary aspergillosis.

Prescribing Information:

Click here for Prescribing Information for CRESEMBA® (isavuconazole) and Vfend (voriconazole)

PP-CRB-GBR-2504. June 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​